Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership
Lynk Pharmaceuticals Co., Ltd. and its U.S. partner Formation Bio announced the dosing of the...
Zai Lab Launches Commercial Rollout of Cobenfy in China Following First Nationwide Prescription for Schizophrenia Treatment
Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) announced the initiation of commercial launch for Cobenfy™...
Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)...
Laekna Therapeutics Secures $527M Global Licensing Deal with Vasque Bio for PI3Kα Inhibitor LAE118, Retaining China Rights
Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced a comprehensive licensing agreement with Vasque Bio,...
Antengene Launches Phase I ATTRACT Study for ATG-201 Bispecific Antibody in Autoimmune Diseases Following $1.18B UCB Licensing Deal
Antengene Corporation (HKG: 6996) announced it has received regulatory clearance from China’s National Medical Products...
Shanghai Bio-heart Secures Israeli Registration for Iberis RDN System – World’s Only Dual-Access Renal Denervation Platform
Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced it has received regulatory approval for...
Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise
Jikeshu (sebaloxavir marboxil), a Category 1 anti-influenza drug jointly developed by Jumpcan Pharmaceutical (SHA: 600566)...
CSPC Pharmaceutical Receives FDA Clearance for Once-Monthly Semaglutide SYH9017 in Weight Management, Challenging Weekly GLP-1 Standard
CSPC Pharmaceutical Group (HKG: 1093) announced today that its GLP-1 receptor agonist semaglutide long-acting injection...
Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia
Lepu Medical Technology (SHE: 300003), a leading provider of cardiovascular disease solutions, announced today that...
Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma’s Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal
Everest Medicines (HKG: 1952) announced this week a strategic licensing agreement with fellow Chinese pharmaceutical...
Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam
Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today plans to sign a “Distribution, Marketing...
European Commission Approves Sanofi’s Subcutaneous Sarclisa (Isatuximab) Across All Multiple Myeloma Indications Based on Phase III IRAKLIA Data
The European Commission announced this week its approval of Sanofi’s (NASDAQ: SNY) Sarclisa (isatuximab) subcutaneous...
Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the U.S. Food and Drug...
Bayer Announces Consumer Health Leadership Restructuring with New Global and U.S. Appointments
Bayer AG (ETR: BAYN) announced today a strategic leadership restructuring within its Consumer Health division,...
RemeGen Secures Dual NMPA Approvals for Tai’ai (Telitacicept) in Sjögren’s Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS/APRIL Inhibitor Franchise
RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) announced today that China’s National Medical Products Administration...
Konruns Pharmaceutical to Acquire 30% Stake in Huamao Pharma for $28.2 Million, Achieving Vertical Integration from API to Finished Formulation
Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced today its strategic acquisition of a 30% stake...
Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors
Adcentrx Therapeutics announced today that China’s National Medical Products Administration (NMPA) has cleared the company’s...
Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data
Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced today that China’s National Medical Products Administration (NMPA)...
Otsuka Pharmaceutical Secures NMPA Approval for Voyxact (Sibeprenlimab) in IgA Nephropathy Based on Pivotal Phase III VISIONARY Data
Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced today that China’s National Medical Products Administration (NMPA)...
Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases
Hangzhou Highlightll Pharmaceutical Co., Ltd., a clinical-stage biopharmaceutical company founded in 2017, has filed a...